George Blumenschein

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Tina Cascone, William N. William, Annikka Weissferdt et al. · Nature Medicine · 2021 · 604 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Roy S. Herbst, David H. Johnson, Eric D. Mininberg et al. · Journal of Clinical Oncology · 2005 · 536 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma

Lajos Pusztai, Peter J. Wagner, Nuhad K. Ibrahim et al. · Cancer · 2005 · 300 citations · Full text

Medicine, Oncology, Pharmacology +15

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Tina Cascone, Cheuk Hong Leung, Annikka Weissferdt et al. · Nature Medicine · 2023 · 206 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer

Francisco Robert, George Blumenschein, Roy S. Herbst et al. · Journal of Clinical Oncology · 2005 · 152 citations · Full text

Medicine, Oncology, Pharmacology +17